Effect of Moringa oleifera on Atherogenic Lipoprotein Indices of HIV Infected Adults on Tenofovir-Based Antiretroviral Regimen in UPTH, Nigeria


The use of the antiviral regimen Tenofovir (TDF) based (Tenofovir/Lamivudine/Efavirenz) for the treatment of HIV has been linked to dyslipidaemia, which is linked to cardiovascular problems and a shorter life span. The study assessed the impact of Moringa oleifera supplementation on metabolic anomalies related to HIV patients on TDF-based regimen using a randomised comparative experiment. The RCT was a trial with two arms that depended on time (intervention TDF-M and control TDF-NM). Out of the 140 individuals that were recruited, 56 were in the TDF-M group (received the Moringa Supplement) and 84 were in the TDF-NM group (control). At baseline, while at lower levels, more than 50% of the patients had abnormal atherogenic lipoprotein indices (Log [TC/HDL-C] = 85.7%; TC/HDL-C = 58.5%; and LDL-C/HDL-C = 51.4%). The proportion of TDF-M individuals at CVD risk has decreased. Following the administration of the Moringa supplement for 12 weeks, the proportion of TDF-NM subjects at risk for CVD increased to 53.6% (x2=26.67, P 0.001), a significant (40.4 percent) drop. Higher TGL and LDL levels were seen in CVD-at-risk HIV patients on a TDF-based regimen, which had an opposite effect on HDL levels and a detrimental effect on atherogenic indices. After 4 weeks (visit 1), the proportion changes between the TDF-M group and the TDF-NM group were not statistically different; however, after 12 weeks (visit 2) of moringa administration, the subjects on moringa had 4.67 [2.39 – 9.13] higher odds of normal API (x2[Yates]=24.688; P0.001), 2.39 [1.58 – 3.60] higher odds of normal TC/HDL-c (x2[Yates]= (P = 0.001; x2[Yates]=23.388). The atherogenic lipoprotein indices of both groups saw significant changes during the research, with the TDF-NM group showing improved values. This supports the argument for using moringa as a dietary supplement to treat dyslipidemia brought on by ART.

Author(s) Details:

C. F. Anyanwu,
Department of Pharmacology, University of Port Harcourt, Rivers State, Nigeria.

G. C. Owhonda,
Directorate of Public Health & Disease Control Services, Rivers State Ministry of Health, Nigeria.

A. W. Obianime,
Department of Pharmacology, University of Port Harcourt, Rivers State, Nigeria.

I. M. Siminialayi,
Department of Pharmacology, University of Port Harcourt, Rivers State, Nigeria.

R. B. Kanee,
Institute of Geoscience and Space Technology, Rivers State University, Port Harcourt, Nigeria.

E. O. Aigbogun Jr.,

Department of Anatomy, Faculty of Basic Medical Sciences, ESUT College of Medicine, Park Ln Hospital Rd, GRA 400102, Enugu, Nigeria.

Please see the link here: https://stm.bookpi.org/CAPR-V5/article/view/7769

Keywords: TDF-based regimen, PLWHA, Moringa oleifera, atherogenic lipoprotein indices, dyslipidemia, UPTH

Leave A Comment